Efficacy of Fufang E’jiao Jiang in the Treatment of Patients with Qi and Blood Deficiency Syndrome: A Real‐World Prospective Multicenter Study with a Patient Registry

Abstract

Objective. This nationwide, multicenter prospective observational study with a patient registry was designed to evaluate the efficacy of Fufang E’jiao Jiang (FEJ) in Chinese patients with Qi and blood deficiency syndrome (QBDS). Methods. QBDS patients were consecutively recruited from 81 investigational sites in China from July, 2019, to December, 2020. Patients who met the eligibility criteria were enrolled in a prospective registry database. Baseline characteristics and changes in scores on the traditional Chinese medicine (TCM) symptom evaluation scale for Qi and blood deficiency, the clinical global impression (CGI) scale, the fatigue scale-14 (FS-14), and the Pittsburgh sleep quality index (PSQI) were analyzed to determine the clinical efficacy of FEJ. Results. A total of 3,203 patients were recruited. The average remission rate (i.e., the sum of the cure rate and improvement rate) of the 20 symptoms of QBDS was 92.49% after 4 weeks of FEJ treatment, which was higher than at baseline; the rate increased to 94.69% at 8 weeks. The CGI scale revealed that the number of total remissions at 4 and 8 weeks was 3,120 (97.41%) and 415 (100%), respectively. The total FS-14 scores decreased by 1.67 ± 4.11 ( p < 0.001 ) at 4 weeks and 1.72 ± 3.09 ( p < 0.001 ) at 8 weeks of treatment. The PSQI scores were 6.6 ± 4.7 and 6.52 ± 3.07 at 4 and 8 weeks, respectively, which were significantly lower than the baseline scores ( p < 0.001 ; p = 0.0033 ). Both the subhealth fatigue (SF) and iron deficiency anemia (IDA) groups showed significantly improved clinical symptoms of QBDS ( p < 0.01 ). Between-group comparisons revealed significantly greater improvements in FS-14 and PSQI scores in the SF group than in the IDA group ( p < 0.05 ). A multivariate logistic regression analysis showed that disease course, FS-14 score at baseline, and four-week FEJ doses were independent risk factors for the degree of symptom relief in QBDS patients ( p < 0.05 ). Conclusion. In real-world settings, FEJ has a promising effect in treating QBDS and can significantly improve the severity of its symptoms.

Khảo Sát Về Hội Chứng Khí Huyết Lưỡng Hư Trên Sinh Viên Năm Thứ Nhất Tại Trường Đại Học Y Dược Cần Thơ Năm 2021-2022

“…Nghiên cứu tác giả Mengjie Zhao đã chỉ ra ba triệu chứng thường gặp nhiều nhất ở bệnh nhân có hội chứng KHLH là hay quên do tinh thần mệt mỏi chiếm 40,37% tương đồng với kết quả của chúng tôi (47,4%). Tuy nhiên, hai triệu chứng thường gặp còn lại trong nghiên cứu của tác giả Mengjie Zhao khác với chúng tôi là vàng da 39,56% và xanh xao 37,93% [8]. Điều này có thể lý giải do đối tượng mà hai nghiên cứu thực hiện là khác nhau về điều kiện sinh hoạt và lứa tuổi.…”

Fufang E’ jiao Jiang’ seffect on immunity, hematopoiesis, and angiogenesis via a systematic “compound-effect-target” analysis

“…It can increase the number of leukocytes and neutrophils in patients with non-small-cell lung cancer [4,5]. It also has a promising effect in treating qi and blood deficiency syndrome (QBDS), and can significantly improve the severity of its symptoms [6]. Otherwise, some active components such as 20S-ginsenoside Rg2, ginsenoside Re etc.…”